False
July 27, 2026
Allogeneic CAR T produces durable responses in advanced kidney cancer, the FDA clears a CD22-directed in vivo therapy, and Repligen agrees to acquire BioLife Solutions for $1.5 billion
4 min read
July 23, 2026
Mission Bio’s Mike Molnar explains how single-cell multiomics could improve vector copy number analysis, product characterization, and safety assessment in CAR T development
5 min read
July 21, 2026
We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality
2 min read
July 20, 2026
First-in-human diabetes cell replacement, early iPSC-derived CAR T data in systemic sclerosis, AAV gene therapy for fragile X syndrome, and fresh funding for off-the-shelf CAR T
4 min read
July 20, 2026
IBTV speaks with industry leaders at Meeting on the Med 2026 to explore how automation, digitization, and new manufacturing models could make cell and gene therapy production more reproducible, efficient, and accessible
1 min read
By Alun Evans, James Strachan
July 15, 2026
In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market
10 min read
July 14, 2026
VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies
3 min read
July 13, 2026
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
4 min read
By Ying K. Tam, Sean Semple
July 13, 2026
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments
6 min read
July 9, 2026
Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality
11 min read
False